Naproxcinod
Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 163133-43-5
- Formule: C18H21NO6
- Masse moléculaire:347.36
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
In Vitro
Naproxcinod (1-30 μM; 15 min) concentration-dependently increases cGMP level up to 27-fold over basal level[1]. Naproxcinod (1-100 μM; 8 h) concentration-dependently increases HO-1 mRNA in endothelial cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Endothelial and gastric mucosal cell lines
-
Concentration:30-1000 μM
-
Incubation Time:8 and 24 hours
-
Result:Increased HO-1 protein levels in endothelial and gastric mucosal cells and increased HO-1mRNA levels in endothelial cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/10 mice with Duchenne muscular dystrophy (DMD)[3]
-
Dosage:0, 10, 21 and 41 mg/kg
-
Administration:Oral gavage; 0-41 mg/kg once daily for 42 weeks
-
Result:Significantly improved fraction shortening and ejection fraction, and reduced inflammation in vivo.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 163133-43-5
-
Masse moléculaire 347.36
-
Formule C18H21NO6
-
SMILES
C[C@@H](C1=CC=C2C=C(OC)C=CC2=C1)C(OCCCCO[N+]([O-])=O)=O
-
Synonyms
AZD 3582; HCT 3012; Nitronaproxen
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Berndt G, et al. A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci. 2004 Feb;21(2-3):331-5. [Content Brief]
[2]. Berndt G, et al. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci. 2005 Jun;25(2-3):229-35. [Content Brief]
[3]. Uaesoontrachoon K, et al. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet. 2014 Jun 15;23(12):3239-49. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)